The estimated Net Worth of Scott G. Davis is at least $432 mil dollars as of 17 August 2023. Scott Davis owns over 37,446 units of Ekso Bionics Inc stock worth over $374,914 and over the last 3 years Scott sold EKSO stock worth over $56,634.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Davis EKSO stock SEC Form 4 insiders trading
Scott has made over 3 trades of the Ekso Bionics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Scott sold 37,446 units of EKSO stock worth $37,446 on 17 August 2023.
The largest trade Scott's ever made was selling 37,446 units of Ekso Bionics Inc stock on 17 August 2023 worth over $37,446. On average, Scott trades about 9,297 units every 97 days since 2022. As of 17 August 2023 Scott still owns at least 331,372 units of Ekso Bionics Inc stock.
You can see the complete history of Scott Davis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Scott Davis's mailing address?
Scott's mailing address filed with the SEC is C/O EKSO BIONICS HOLDINGS, INC., 101 GLACIER POINT, SUITE A, SAN RAFAEL, CA, 94904.
Insiders trading at Ekso Bionics Inc
Over the last 9 years, insiders at Ekso Bionics Inc have traded over $898,173 worth of Ekso Bionics Inc stock and bought 276,997 units worth $399,153 . The most active insiders traders include Theodore T Wang, Steven Sherman y Russ Angold. On average, Ekso Bionics Inc executives and independent directors trade stock every 56 days with the average trade being worth of $25,243. The most recent stock trade was executed by Scott G. Davis on 17 August 2023, trading 37,446 units of EKSO stock currently worth $37,446.
What does Ekso Bionics Inc do?
since 2005, ekso bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. the company’s first commercially available product called ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. by designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, ekso bionics is helping people rethink current physical limitations and achieve the remarkable. ekso bionics is headquartered in richmond, california international offices: europe/middle east/africa 29th floor one canada square canary wharf london, united kingdom +44 20 7060 3568 kunden service deutschland +49 89 55067774
What does Ekso Bionics Inc's logo look like?
Complete history of Scott Davis stock trades at Ekso Bionics Inc
Ekso Bionics Inc executives and stock owners
Ekso Bionics Inc executives and other stock owners filed with the SEC include:
-
Jack Peurach,
President, Chief Executive Officer, Director -
William R. Shaw,
Chief Commercial Officer -
John Glenn,
Chief Financial Officer -
Jack Peurach,
Pres, CEO & Director -
John F. Glenn,
CFO & Sec. -
Jason Jones,
Vice-President of Product Development -
Steven A. Sherman,
Exec. Chairman -
Steven Sherman,
Executive Chairman of the Board -
David Carey,
IR Contact Officer -
William Shaw,
Chief Commercial Officer -
Stanley Stern,
Independent Director -
Marilyn Hamilton,
Independent Director -
Theodore Wang,
Director -
Thomas Schreck,
Independent Director -
Charles Li,
Independent Director -
Jerome Wong,
Corp. Controller -
Foon Lim Chwee,
Pres of APAC -
Anthony Pratt,
US Director of Sales -
Rachael Anderson,
Global Director of Marketing & Strategic Growth -
Scott G. Davis,
President & COO -
Theodore T Puissance Cross ...,
-
Russ Angold,
President, Ekso Labs -
Tom Looby,
President & Chief Com. Officer -
Kecheng Li,
Director -
Russ De Lonzor,
Vice Pres., Operations -
Max Scheder Bieschin,
Chief Financial Officer -
Gregory Davault,
Vice Pres., Global Marketing -
Daniel Boren,
Director -
Amy Mc Bride Wendell,
Director -
Howard D Palefsky,
Director -
Nathan Harding,
Chief Executive Officer -
Rhonda A. Wallen,
Director -
Mary Ann Cloyd,
Director -
Corinna Lathan,
Director -
Deborah Lafer Scher,
Director -
Jerome Wong,
Chief Financial Officer